Why Did Novo Nordisk (NVO) Go Down on Friday?

We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other firms that took a hit on Friday.

Wall Street’s main indices all finished in the green territory on Friday, as investors repositioned their portfolios ahead of president-elect Donald Trump’s return to office.

The Dow jumped by 0.78 percent, while the S&P surged by 1 percent. Meanwhile, Nasdaq soared 1.51 percent.

However, ten companies under mixed sectors bucked an overall positive market sentiment as multiple negative factors put pressure on investor sentiment. In this article, let’s look at the reasons that dragged their shares performance.

To come up with the top 10 losers, we considered only the stocks with at least $2 billion in market capitalization and $5 million in daily trading volume.

Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S, a multinational pharmaceutical company, saw its share prices on Friday retreat by 5.27 percent to finish at $78.69 after following news that the company’s blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027.

A report said Friday that the negotiation process was in line with outgoing president Joe Biden’s signature Inflation Reduction Act of 2022, where 15 new drugs are set to undergo a negotiation process for being among the most expensive drugs.

It can be learned that drug pricing concerns have already helped drag down the company’s valuation last year, alongside increasing competition for its blockbuster obesity and diabetes medicines.

Novo Nordisk is a Denmark-based firm that owns drug brands such as Levemir, Tresiba, NovoLog, Novolin R, and Novolin N.

READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap

This article is originally published at Insider Monkey.